News

Filter

1 to 9 of 63 results

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

27-11-2014

US pharma major Bristol-Myers Squibb has received a Complete Response Letter from the US Food and Drug…

Anti-viralsBristol-Myers SquibbdaclatasvirPharmaceuticalRegulationUSA

Bristol-Myers reveals access plan for hep C drug daclatasvir

03-11-2014

US Pharma major Bristol-Myers Squibb has recently revealed a commercial strategy for sales of its new…

Anti-viralsBristol-Myers SquibbdaclatasvirDaklinzaMarkets & MarketingPharmaceuticalPricing

Bristol-Myers resolves Sustiva patent litigation in USA

Bristol-Myers resolves Sustiva patent litigation in USA

08-10-2014

US pharma major Bristol-Myers Squibb has successfully resolved all outstanding US patent litigation relating…

Anti-viralsAtriplaBristol-Myers SquibbCiplaLegalMerck & CoPatentsPharmaceuticalSustivaUSA

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

08-10-2014

Bristol-Myers Squibb has decided that it will not pursue US Food and Drug Administration approval of…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirGenotypeGilead SciencesMarkets & MarketingPharmaceuticalRegulationSovaldiUnited StatesUS Food and Drug AdministrationUSA

Teva launches generic Baraclude in the USA

Teva launches generic Baraclude in the USA

04-09-2014

Israeli generics giant Teva Pharmaceutical Industries says it has launched its generic equivalent to…

Anti-viralsBaracludeBristol-Myers SquibbGenericsMarkets & MarketingTeva Pharmaceutical IndustriesUSA

Bristol-Myers’ hep C drug Daklinza approved in Europe

Bristol-Myers’ hep C drug Daklinza approved in Europe

27-08-2014

US pharma major Bristol-Myers Squibb says that the European Commission has approved Daklinza (daclatasvir),…

Anti-viralsBristol-Myers SquibbDaklinzaEuropeGilead SciencesPharmaceuticalRegulationSovaldi

Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

17-07-2014

Ahead of the International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool has announced…

Anti-viralsatazanavirBristol-Myers SquibbdolutegravirGenericsGilead SciencesMedicines Patent PoolRoche

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

07-07-2014

The Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), a potent, pan-genotypic…

Anti-viralsBristol-Myers SquibbDaklinzaDaklinza+SunvepraJapanPharmaceuticalRegulationSunvepra

1 to 9 of 63 results

COMPANY SPOTLIGHT

Menarini

Back to top